You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting endothelial arginase to treat diabetes-associated vascular dysfunction

    SBC: ARGINETIX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-inflammatory pathways, although other anti-inflammatory ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. COA360: Measuring Cultural Competence in Healthcare

    SBC: DayStar Research            Topic: NIMHD

    DESCRIPTION (provided by applicant): This Phase 1 STTR application seeks support for research to enhance the commercial viability of a tool to assess the cultural competence of health care organizations. The tool was developed by Dr. Thomas A. LaVeist, who is director of the Hopkins Center for Health Disparities Solutions at the Johns Hopkins Bloomberg School of Public Health. The Cultural-comp ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Low-Cost, Noninvasive Liver Iron Measurements in African American Iron Overload

    SBC: Avrin, William F.            Topic: NIMHD

    DESCRIPTION (provided by applicant): This STTR program will test the utility of a low-cost device for noninvasive liver iron measurements, by using the device to determine the prevalence of iron overload in African Americans. African American iron overload is both an under-studied health issue in a medically underserved population, and an example of the wider problem of mild to moderate iron overl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Real-Time Optical Feedback for the Control of In Vivo Nanoparticle Concentration

    SBC: NANOSPECTRA BIOSCIENCES, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): There is an immediate and urgent clinical need to enhance the monitoring of the delivery and accuracy of targeted drug delivery, the onset and spread of cancers, and the longitudinal monitoring of cancer treatments. Nanotechnology holds the promise to address this problem. A smart particle capable of selective targeting would augment the physician's tools nee ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a BBB Model to Study Transendothelial Cell Migration

    SBC: Flocel Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): Increasing evidence indicates that systemic inflammation and the blood-brain barrier (BBB), which becomes the target of overreacting or misguided immune cells that determine BBB failure and immune extravasations into the brain parenchyma, are involved in the pathogenesis of neurological diseases such as meningitis, inflammation, Alzheimer's disease, and multipl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Neuroprotective therapy of stroke with HUCNC and simvastatin

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government